28 New Drug Approvals In EU: Cancer Dominates, But RA, Skin & Blood Disorders Well Served Too
Twenty-eight new products containing a total of 29 new active substances were authorized for marketing in the EU in 2017, very much line with the 2016 tally. As in that year, oncology dominated the 2017 approvals, which also included new drugs for rheumatoid arthritis, skin & blood disorders, and hepatitis C.
You may also be interested in...
AVEO’s Fotivda: US FDA Concerns About Overall Survival Put To Rest By TIVO-3 Final Analysis
After repeatedly advising against tivozanib NDA submission on the basis of interim overall survival data that suggested a negative trend, agency ultimately concluded the final analysis did not suggest a detrimental effect in third-line renal cell carcinoma even though median overall survival was shorter than for the comparator agent, Bayer’s Nexavar.
Steba’s Tookad: US FDA Panel To Weigh Novel Endpoints, Missing Data And Toxicities
Sponsor seeks accelerated approval for low-risk, early-stage prostate cancer based on a trial that met its coprimary endpoints, but agency says interpretation of those results is complicated by novelty of the outcomes, data quality issues and increase in genitourinary adverse events.
Five Biologic Blockbusters Opened Up To EU Biosimilar Competition In 2017
A total of 16 biosimilar products were approved in 2017, including the first competitors to five biologic blockbusters. Coincidentally, 16 other biosimilars are also under evaluation by the European Medicines Agency’s main scientific committee, the CHMP, including six versions of Amgen’s Neulasta (pegfilgrastim) and five more biosimilars of AbbVie’s Humira.